In a significant development, US President Donald Trump has granted an exemption to Indian pharmaceutical products from the new reciprocal tariffs, which is a major win for the Indian pharmaceutical sector. This exemption is poised to benefit India’s pharmaceutical industry significantly, which plays a crucial role in providing affordable medicines not only in the domestic market but also globally. The Indian pharmaceutical sector is a key contributor to the country’s economy, with the US market accounting for a substantial 30% of Indian pharmaceutical exports. This move by President Trump is expected to bolster the Indian pharmaceutical industry’s growth and stability, further solidifying its position as a global leader in the pharmaceutical market. The exemption from reciprocal tariffs is a welcome relief for Indian pharmaceutical companies, as it will help in maintaining their competitive edge in the US market and ensure continued access to one of the largest pharmaceutical markets in the world. This decision is likely to have a positive impact on the Indian economy, strengthening trade relations between the two countries and fostering greater collaboration in the pharmaceutical sector.